News & Updates

Show Multimedia Only

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

Using atezolizumab in addition to pertuzumab plus high-dose trastuzumab does not appear to improve central nervous system (CNS) responses in HER2-positive breast cancer patients with brain metastases, according to the results of a single-arm phase II study.

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

Study pinpoints factors affecting cervical cancer screening participation in Singapore

13 Nov 2024 by

Cervical cancer screening uptake remains suboptimal in Singapore, with uptake influenced by demographic factors, screening knowledge and awareness, health-related belief and behaviour, according to a study.

Study pinpoints factors affecting cervical cancer screening participation in Singapore

13 Nov 2024

Early smoking cessation boosts cancer survival

12 Nov 2024

Quitting smoking within 6 months after receiving a cancer diagnosis appears to confer survival benefits, according to a study.

Early smoking cessation boosts cancer survival

12 Nov 2024

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

12 Nov 2024 by

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

12 Nov 2024

Aumolertinib ups PFS in EGFR-mutated NSCLC

08 Nov 2024 by

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024.

Aumolertinib ups PFS in EGFR-mutated NSCLC

08 Nov 2024

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

Modified CXI predicts survival in CRC after surgery

06 Nov 2024 by

The modified cachexia index (mCXI) is effective in predicting the survival outcomes in patients with colorectal cancer (CRC) following radical surgery, reports a study.

Modified CXI predicts survival in CRC after surgery

06 Nov 2024

Is rapid-rate oxaliplatin safer than standard infusion?

06 Nov 2024

Rapid infusion of oxaliplatin appears to have minimal treatment modifications relative to standard administration but may lead to a higher incidence of peripheral neuropathy (PN), according to a study.

Is rapid-rate oxaliplatin safer than standard infusion?

06 Nov 2024

Pegaspargase biosimilar safe to use in childhood ALL

05 Nov 2024

The biosimilar Pegaspargase, when combined with chemotherapy, demonstrates a favourable safety profile in children with acute lymphoid leukemia (ALL) treated according to ICiCLe ALL-14 protocol, a study has shown.

Pegaspargase biosimilar safe to use in childhood ALL

05 Nov 2024

Two patients with advanced endometrial cancer treated with chemo-IO

05 Nov 2024 by

A 59-year-old female was referred for management of suspected primary carcinoma of the peritoneum in August 2023. She complained of right flank pain and abdominal distention during the previous month. An abdominopelvic (AP) CT scan showed right hydronephrosis and hydroureter along with multiple peritoneal and omental (largest 4.3 x 12.1 x 4.5 cm) masses, as well as a pancreatic tail lesion. There were no enlarged lymph nodes (LNs). Gross ascites and moderate left pleural effusion were present without a pleural mass. Her Eastern Cooperative Oncology Group performance status (ECOG PS) was 1.

Two patients with advanced endometrial cancer treated with chemo-IO

05 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

Study pinpoints factors affecting cervical cancer screening participation in Singapore

Study pinpoints factors affecting cervical cancer screening participation in Singapore

Early smoking cessation boosts cancer survival

Early smoking cessation boosts cancer survival

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

Aumolertinib ups PFS in EGFR-mutated NSCLC

Aumolertinib ups PFS in EGFR-mutated NSCLC

Original New Drug Application Approvals by US FDA (16-31 October 2024)

Original New Drug Application Approvals by US FDA (16-31 October 2024)

Modified CXI predicts survival in CRC after surgery

Modified CXI predicts survival in CRC after surgery

Is rapid-rate oxaliplatin safer than standard infusion?

Is rapid-rate oxaliplatin safer than standard infusion?

Pegaspargase biosimilar safe to use in childhood ALL

Pegaspargase biosimilar safe to use in childhood ALL

Two patients with advanced endometrial cancer treated with chemo-IO

Two patients with advanced endometrial cancer treated with chemo-IO